Indusatumab vedotin
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin. Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis[1].
Product Specifications
CAS Number
1514889-12-3
Product Name Alternative
MLN0264; TAK-264
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis; Guanylate Cyclase
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
96.37
Solubility
10 mM in DMSO
Smiles
[Indusatumabvedotin]
References & Citations
[1]Schreiber AR, et al. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018;5 (1) :42-49. |[2]Teng S W, et al. Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models[J]. Cancer Research, 2014, 74 (19_Supplement) : 4649-4649.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
